Based upon recently published information in the journal Science, would you offer zileuton to a high-risk food allergy patient who declines oral immunotherapy and omalizumab?  

It was recently reported in the journal Science (Hoyt et al., PMID 40773557) that the asthma drug zileuton blocks the pathway of DPEP1, a gene that is essential in regulating anaphylaxis. In their study, scientists nearly eliminated allergic responses in mice that were previously highly susceptible to food-induced anaphylaxis.